Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FCB Health Adds Kim Barke as Group Creative Director to Lead Oncology Accounts

NYC-based FCB Health appointed Kim Barke to the role of group creative director to lead its oncology accounts.

Read More »

Birth weight may impact intelligence throughout life

Being born at below-normal weight is associated with a lower intelligence quotient (IQ) not only in childhood and young adulthood, but even at age 50, according to a new study from Denmark.

Read More »

Biogen Acquires Remedy Pharmaceuticals’ Cirara

Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.

Read More »

India’s drug pricing regulator clamps down on drug cocktails

India’s drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval.

Read More »

Democratic attorneys general seek to intervene in Obamacare case

More than a dozen Democratic attorneys general sought to intervene to defend a key part of the Obamacare healthcare law – subsidy payments to insurance companies – which is under threat in a court case.

Read More »

GlycoMimetics Stock Takes Off on Positive Phase II Leukemia Data, Breakthrough Tag

Rockville, Mary.-based GlycoMimetics’ shares jumped dramatically on the news of positive interim Phase II data for GMI-1271 for acute myeloid leukemia.

Read More »

Teva Cuts Another 500 Jobs, May Hire CEO Who Isn’t Israeli

As Teva Pharmaceutical narrows down its candidate for a new chief executive officer, the company is shuttering a plant in Hungary and laying off 500 employees, according to reports.

Read More »

Shire’s Lanadelumab Wows in Phase III Study

Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.

Read More »

FDA Approves Kalydeco for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Read More »

FDA clinical hold on Concert’s hair loss drug

Concert Pharmaceuticals Inc. said the U.S. FDA imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom